Tryptophan metabolism and its relationship with depression and cognitive impairment among HIV-infected individuals

International Journal of Tryptophan Research

Volumn 9, Issue 1, 2016, Pages 79-88

  Keegan, Michael R ^a,b   Chittiprol, Seetharamaiah ^c,d   Letendre, Scott L ^c   Winston, Alan ^a   Fuchs, Dietmar ^e   Boasso, Adriano ^a   Iudicello, Jennifer ^c   Ellis, Ronald J ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VIIV HEALTHCARE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Memorial Healthcare System   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cognitive impairment; Depression; HIV; IDO; Kynurenine; Tryptophan

Indexed keywords

EID: 85009901979     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S36464     Document Type: Article

References (81)

1. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005;111(2):194-213.
2. Berger-Greenstein JA, Cuevas CA, Brady SM, Trezza G, Richardson MA, Keane TM. Major depression in patients with HIV/AIDS and substance abuse. AIDS Patient Care STDS. 2007;21(12):942-55.
3. Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology. 2006;3:28.
4. Nelson M, Manjii H, Wilkins E. Central nervous system opportunistic infections. HIV Med. 2011;12(suppl 2):8-24.
5. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29(10):865-74.
6. Morrison MF, Petitto JM, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002;159(5):789-96.
7. Nott KH, Vedhara K. Nature and consequences of stressful life events in homosexual HIV-positive men: a review. AIDS Care. 1999;11(2):235-43.
8. Lichtenstein B, Laska MK, Clair JM. Chronic sorrow in the HIV-positive patient: issues of race, gender, and social support. AIDS Patient Care STDS. 2002;16(1):27-38.
9. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-7.
10. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002;24(1):43-47.
11. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175-83.
12. Heaton RK, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc. 1995;1(3): 231-51.
13. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915-21.
14. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-50.
15. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
16. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087-96.
17. Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials. 2011;12:333-8.
18. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19:152-68.
19. Spudich S. HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep. 2013;10:235-43.
20. Minagar A, Commins D, Alexander JS, et al. NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. Mol Diagn Ther. 2008;12(1):25-43.
21. Schmitz G, Leuthauser-Jaschinski K, Oros E. Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases? Cent Nerv Syst Agents Med Chem. 2009;9:307-30.
22. Stone TW. Neuropharmacology of quinolinic acid and kynurenic acids. Pharmacol Rev. 1993;45(3):309-79.
23. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol. 2003;527:105-12.
24. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2:45-60.
25. Boasso A, Shearer GM. How does indoleamine 2, 3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab. 2007;8:217-23.
26. Mehraj V, Routy J-P. Tryptophan catabolism and chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;8:41-8.
27. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2004;49:15-23.
28. Davies NWS, Guillemin G, Brew BJ. Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder. Int J Tryptophan Res. 2010;3: 121-40.
29. Capuron L, Schroecksnadel S, Feart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70:175-82.
30. Murray M. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis. 2003;3:644-52.
31. Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res. 1990;10: 599-603.
32. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69-74.
33. Heyes MP, Brew BJ, Saito K, et al. Interrelationships between quinolinic acid, neuroactive kynurenines, neopterin and β2-microglobulin in cerebrospinal fluid and serum of HIV-1 infected patients. J Neuroimmunol. 1992;40:71-80.
34. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production, tryptophan degradation, and mental depression-what is the link? Brain Behav Immun. 2002;16:590-5.
35. Møller SE. Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta Psychiatr Scand Suppl. 1985;325:3-31.
36. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 1994;10:947-51.
37. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858-62.
38. Martinez P, Tsai AC, Muzoora C, et al. Reversal of IDO-induced tryptophan catabolism may mediate antiretroviral therapy-related improvements in HIV-infected Ugandans. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8. Seattle, WA: 2012:462.
39. Schroeksnadel K, Sarcletti M, Winkler C, et al. Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun. 2008;22:881-9.
40. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr. 1990;3(9):873-6.
41. Hagberg L, Cinque P, Gisslén M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.
42. Grill M, Gisslen M, Cinque P, et al. Kynurenine-tryptophan and phenylalanine-tyrosine levels in cerebrospinal fluid in HIV infection. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8. Seattle, WA: 2012:463.
43. van Donkelaar EL, Blokland A, Ferrington L, Kelly PA, Steinbusch HW, Prickaerts J. Mechanism of acute tryptophan depletion: is it only serotonin? Mol Psychiatry. 2011;16:695-713.
44. Fuchs D, Möller AA, Reibnegger G, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett. 1991;28(3):207-12.
45. Marquine MJ, Umlauf A, Rooney AS, et al. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014;65:190-7.
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington, DC; 2000.
47. Kessler RC, Andrews G, Mroczek D, Ustun TB, Wittchen H-U. The World Health Organization composite international diagnostic interview short form (CIDI-SF). Int J Methods Psychiatr Res. 1998;7(4):171-85.
48. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz: Psychological Assessment Resources, Inc; 2004.
49. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26(3):307-19.
50. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43:2424-6.
51. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem. 2002;48:579-81.
52. Neurauter G, Scholl-Bürgi S, Haara A, et al. Simultaneous measurement of phenylalanine and tyrosine by high performance liquid chromatography (HPLC) with fluorescence detection. Clin Biochem. 2013;46:1848-51.
53. Griess P. Bemerkungen zu der Abhandlung der HH. Weselky und Benedikt "Ueber einige Azoverbindungen". Chem Ber. 1879;12:426-8.
54. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. Adaptation of the Griess reaction for detection of nitrite in human plasma. Free Radic Res. 2004;38:1235-40.
55. Perrella O, Carrieri PB, Guarnaccia D, Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J Neurol. 1992;239:387-8.
56. Mastroianni CM, Paoletti F, Valenti C, Vullo V, Jirillo E, Delia S. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry. 1992;55(3):219-21.
57. Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis. 1998;178(4):1000-7.
58. Lafeuillade A, Poggi C, Pellegrino P, Corti K, Profizi N, Sayada C. HIV-1 replication in the plasma and cerebrospinal fluid. Infection. 1996;24(5):367-71.
59. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol. 1990;28(4):556-60.
60. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS. 2002;16(16):2145-9.
61. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996;174(2):294-8.
62. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251-8.
63. Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med. 2007;85:1351-9.
64. Baran H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm. 2000;107(10):1127-38.
65. Murray MF. Insights into therapy: tryptophan oxidation and HIV infection. Sci Transl Med. 2010;2(32):32 s23.
66. Huang Y, Zhao L, Jia B, et al. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci. 2011;31(42):15195-204.
67. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
68. Tavares RG, Tasca CI, Santos CE, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int. 2002;40:621-7.
69. Heyes MP, Brew B, Martin A, et al. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Adv Exp Med Biol. 1991;294:687-690.
70. Brew BJ, Letendre SL. Biomarkers of HIV-related central nervous system disease. Int Rev Psychiatry. 2008;20(1):73-88.
71. Martin A, Heyes MP, Salazar AM, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci. 1992;4:270-9.
72. Valle M, Price RW, Nilsson A, Heyes M, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004;127:1047-60.
73. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol. 2002;104:242-7.
74. Foster AC, Vezzani A, Frencg ED, Schwarz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984;48:273-8.
75. Andine P, Lehmann A, Ellren K, et al. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett. 1988;90:208-12.
76. Launay JM, Copel L, Callebert J, et al. Decreased whole blood 5-hydroxytryptamine (serotonin) in AIDS patients. J Acquir Immune Defic Syndr. 1988;1(4):324-5.
77. Larsson M, Hagberg L, Norkrans G, Forsman A. Indoleamine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res. 1989;23(4):441-446.
78. Caballero J, Nahata MC. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother. 2005;39(1):141-5.
79. Murray MF. The human indoleamine 2, 3-dioxygenase gene and related human genes. Curr Drug Metab. 2007;8:197-200.
80. Strasser B, Gostner JM, Fuchs D. Mood, food and cognition: role of tryptophan and serotonin. Curr Opin Clin Nutr Metab Care. 2016;19:55-61.
81. Hannemann J, Singer M, Primetshofer M, et al. Complex connections between marital satisfaction and urinary neopterin concentrations in a woman with breast cancer. 34th International Winter-Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics, February 24th-27th. Innsbruck, Austria: 2015. Oral presentation and Abstract.